RNXT · Company research
RenovoRx, Inc. Common Stock (RNXT): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
17records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Renovorx Stock Price Forecast. Should You Buy RNXT? - StockInvest.us | Renovorx Stock Price Forecast. Should You Buy RNXT? StockInvest.us | View source ↗ | StockInvest.us | Oct 16, 2026 | neutral | 0 | 0.6 |
| RenovoRx, Inc. SEC Filing (Oct 16, 2026) - Stock Titan | RenovoRx, Inc. SEC Filing (Oct 16, 2026) Stock Titan | View source ↗ | Stock Titan | Oct 16, 2026 | neutral | 0 | 0.6 |
| A director receives 55,924 RenovoRx (RNXT) stock options with a $1.55 exercise price. - Stock Titan | A director receives 55,924 RenovoRx (RNXT) stock options with a $1.55 exercise price. Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| A director receives 55,924 RenovoRx (RNXT) stock options exercisable at $1.55 per share. - Stock Titan | A director receives 55,924 RenovoRx (RNXT) stock options exercisable at $1.55 per share. Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| Two patients with inoperable pancreatic tumors showed responses after local chemotherapy. - Stock Titan | Two patients with inoperable pancreatic tumors showed responses after local chemotherapy. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| RenovoRx Inc. (RNXT) Slips 2.31% to $1.69 as Shares Press Toward Support at $1.61 - Revenue Weighted - https://www.dars.gov.et/ | RenovoRx Inc. (RNXT) Slips 2.31% to $1.69 as Shares Press Toward Support at $1.61 - Revenue Weighted https://www.dars.gov.et/ | View source ↗ | https://www.dars.gov.et/ | Sep 20, 2026 | neutral | 0 | 0.6 |
| RenovoRx study: About 51% of a chemotherapy drug was extracted at the tumor site - Stock Titan | RenovoRx study: About 51% of a chemotherapy drug was extracted at the tumor site Stock Titan | View source ↗ | Stock Titan | Aug 25, 2026 | neutral | 0 | 0.6 |
| RenovoRx Regains Nasdaq Compliance on Minimum Bid Price - The Globe and Mail | RenovoRx Regains Nasdaq Compliance on Minimum Bid Price The Globe and Mail | View source ↗ | The Globe and Mail | Aug 21, 2026 | neutral | 0 | 0.6 |
| RenovoRx’s cancer drug-delivery device now has 20 issued or allowed patents - Stock Titan | RenovoRx’s cancer drug-delivery device now has 20 issued or allowed patents Stock Titan | View source ↗ | Stock Titan | Aug 20, 2026 | neutral | 0 | 0.6 |
| RenovoRx Inc (NASDAQ: RNXT) Stock Price, News & Analysis - kalkine.ca | RenovoRx Inc (NASDAQ: RNXT) Stock Price, News & Analysis kalkine.ca | View source ↗ | kalkine.ca | Aug 14, 2026 | neutral | 0 | 0.6 |
| RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance | RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Aug 12, 2026 | neutral | 0 | 0.6 |
| RenovoRx Inc (RNXT) Q2 2026: Everything You Need To Know Ahead Of Earnings - Yahoo Finance | RenovoRx Inc (RNXT) Q2 2026: Everything You Need To Know Ahead Of Earnings Yahoo Finance | View source ↗ | Yahoo Finance | Aug 11, 2026 | neutral | 0 | 0.6 |
| RenovoRx, Inc. (NASDAQ:RNXT): Are Analysts Optimistic? - Simply Wall Street | RenovoRx, Inc. (NASDAQ:RNXT): Are Analysts Optimistic? Simply Wall Street | View source ↗ | Simply Wall Street | Jul 28, 2026 | neutral | 0 | 0.6 |
| RenovoRx Granted Extended Nasdaq Compliance Period Amid Listing Risk - The Globe and Mail | RenovoRx Granted Extended Nasdaq Compliance Period Amid Listing Risk The Globe and Mail | View source ↗ | The Globe and Mail | Jul 3, 2026 | neutral | 0 | 0.6 |
| RNXT Forecast — Price Target — Prediction for 2027 - TradingView | RNXT Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 26, 2026 | neutral | 0 | 0.6 |
| RenovoRx, Inc. Reports Q3 2025 Financial Results with $10 Million in Cash and Positive Revenue Growth Prospects - Quiver Quantitative | RenovoRx, Inc. Reports Q3 2025 Financial Results with $10 Million in Cash and Positive Revenue Growth Prospects Quiver Quantitative | View source ↗ | Quiver Quantitative | Nov 13, 2025 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Feb 16, 2024 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.